As of 6 Nov 2026, Makers Laboratories trades at 37.2× trailing earnings, above the industry P/E of 28.7×. Sales grew 11% a year over 3 years; its ROCE of 9.0% is the lowest among the 7 largest Drug Manufacturers (Specialty & Generic) peers. It carries very little debt. It is a small-cap company with a market cap of ₹127 Cr, ranked 112th of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares rose 37% over the past year.
- ₹222.75
- ₹222.75
- ₹212.00
- ₹219.44
- 4.7K
Health check
- ReturnsAhead
+37.3% over a year, better than 5 of 7 peers.
- Price tagPricier
P/E 37.2 vs industry 28.7.
- GrowthStrong
Sales +11.4% a year over 3 years.
- ProfitabilityWeak
ROCE 9.0% vs peer median 17.9%.
- Balance sheetFair
Practically debt-free, Piotroski 5 of 9.
- Red flags1 to check
Return on equity is low at 3.3%.
Small cap
Market sensitivity
Key metrics
- Market cap
- ₹127 Cr
- Small cap
- P/E
- 37.2
- Industry 28.7
- Price to book
- 1.74
- Peers 4.99
- Dividend yield
- 0.00%
- ROE
- 3.3%
- Peers 14.7%
- ROCE
- 9.0%
- Peers 17.9%
- Debt to equity
- 0.05
- Debt ₹6.12 Cr
- EPS (TTM)
- ₹5.79
- Face value ₹10
- OPM (TTM)
- 12.6%
- Net margin 2.3%
- Sales growth
- +22.2%
- Latest quarter vs a year ago
- Profit growth
- +244.5%
- Latest quarter vs a year ago
- Price to sales
- 0.85
- EV/EBITDA 9.3
Strengths and risks
Strengths
- Practically debt-free.
- Quarterly profit up 244.5% on a year ago.
- Quarterly sales up 22.2% on a year ago.
Risks to check
- Return on equity is low at 3.3%.
About Makers Laboratories
Makers Laboratories Limited, an integrated pharmaceutical company, manufactures and markets formulations in India. It operates in two segments, Pharmaceutical and Chemical Manufacturing. The company offers general health therapeutic products, including acid regulatory, anthelmintic, anti-allergic, anti-asthmatic, anti-biotic, anti-diabetics, anti-diarrhoeals, anti-emetics and anti-nauseants, anti-fungal, anti-hypertensive, antiinflammatory, analgesic,…
- Headquarters
- Mumbai
- Employees
- 114
- Sector
- Healthcare
- ISIN
- INE987A01010
- Website
- makerslabs.com
Price range
- Avg volume (3M)
- 8.4K
- 1-year return
- plus 37.3%
- From 52-week high
- minus 8.8%
Peers · Drug Manufacturers - Specialty & Generic
| Company | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMASun Pharmaceutical Industries | 1,860.00 | plus 1.69% | 4,46,276 | 40.7 | 4.99 | 17.9% | 13.1% | 28.2% | 10.4% | 10.6% | 0.87% | plus 8.2% |
| DIVISLABDivi's Laboratories | 10,320.50 | plus 1.78% | 2,73,977 | 93.6 | 16.35 | 19.0% | 16.2% | 34.9% | 11.0% | 12.1% | 0.30% | plus 49.0% |
| TORNTPHARMTorrent Pharmaceuticals | 4,750.00 | plus 0.85% | 1,80,675 | 80.2 | 9.83 | 9.1% | 15.7% | 33.7% | 13.3% | 20.2% | 0.81% | plus 31.7% |
| LAURUSLABSLaurus Labs | 2,340.00 | minus 0.26% | 1,26,433 | 94.4 | 20.86 | 19.5% | 24.0% | 30.4% | 3.8% | 4.0% | 0.09% | plus 138.6% |
| ZYDUSLIFEZydus Lifesciences | 1,197.90 | plus 0.41% | 1,19,491 | 28.6 | 4.29 | 19.0% | 14.7% | 26.2% | 16.5% | 37.0% | 0.08% | plus 22.8% |
| DRREDDYDr. Reddy's Laboratories | 1,373.00 | plus 0.51% | 1,14,462 | 40.9 | 2.96 | 14.2% | 7.3% | 15.9% | 11.0% | −1.7% | 0.59% | plus 13.8% |
| CIPLACipla | 1,411.00 | plus 0.49% | 1,13,993 | 39.4 | 3.22 | 14.9% | 8.3% | 17.3% | 7.2% | 11.5% | 0.93% | minus 6.6% |
| MAKERSLMakers Laboratories | 215.20 | minus 1.93% | 127 | 37.2 | 1.74 | 9.0% | 3.3% | 13.6% | 11.4% | – | 0.00% | plus 37.3% |
| Median of 7 peers | – | 0.51% | 1,26,433 | 40.9 | 4.99 | 17.9% | 14.7% | 28.2% | 11.0% | 11.5% | 0.59% | 22.8% |
Quarterly results
| ₹ Cr | Jun 25 | Sep 25 | Dec 25 | Mar 26 | Jun 26 |
|---|---|---|---|---|---|
| 35 | 34.2 | 35.7 | 35.8 | 42.8 | |
| 32 | 31.9 | 31.5 | 30.5 | 35.8 | |
| 3 | 2.3 | 4.2 | 5.3 | 7 | |
| 8.6% | 6.7% | 11.7% | 14.8% | 16.3% | |
| 0.3 | 0.4 | 0.3 | 0.8 | 0.6 | |
| 0.2 | 0.2 | 0.2 | 0.2 | 0.1 | |
| 1.1 | 1.1 | 1.1 | 1.1 | 1.1 | |
| 2 | 1.3 | 3.1 | 4.7 | 6.3 | |
| 34.9% | 42.3% | 27.9% | 24.8% | 27.0% | |
| 0.4 | −0.1 | 0.9 | 1.1 | 1.5 | |
| 0.74 | -0.20 | 1.59 | 1.85 | 2.55 |
Profit & loss
- Sales CAGR 3Y
- +11.4%
- ROE
- 3.3%
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 101 | 104 | 120 | 140 | |
| – | +2.9% | +15.7% | +16.2% | |
| 97.3 | 102 | 111 | 125 | |
| 3.5 | 1.3 | 9 | 15 | |
| 3.5% | 1.3% | 7.5% | 10.7% | |
| 2.2 | 1.4 | 0.9 | 1.4 | |
| 2.1 | 2 | 1.3 | 0.8 | |
| 4.2 | 4.5 | 4.8 | 4.5 | |
| −0.2 | −0.1 | 9.6 | 0.1 | |
| −0.8 | −3.9 | 13.4 | 11.1 | |
| −161.4% | −22.8% | 18.7% | 29.5% | |
| −4.8 | −6.3 | 7.5 | 2.4 | |
| -7.90 | -10.62 | 12.70 | 3.99 |
Forecast
Balance sheet
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 5.9 | 5.9 | 5.9 | 5.9 | |
| 63.3 | 57.1 | 64.6 | 67 | |
| 13.4 | 19.5 | 5.1 | 6.1 | |
| 69.7 | 78.7 | 72.4 | 87.6 | |
| 152 | 161 | 148 | 167 | |
| 84.3 | 85.8 | 73.9 | 73.4 | |
| 0.5 | 0.3 | 0.8 | 3.8 | |
| 0.1 | 0.1 | 0.1 | 0.2 | |
| 3.9 | 4.6 | 0.2 | 11.8 | |
| 63.5 | 70.4 | 72.9 | 77.5 | |
| 152 | 161 | 148 | 167 |
Cash flow
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| −8.6 | 0.8 | −4.1 | 14.3 | |
| 1.3 | −6.9 | 19.7 | −14.7 | |
| 5.8 | 5.7 | −15.8 | 0.4 | |
| −1.6 | −0.3 | −0.2 | −0 | |
| −12.9 | −6.6 | −3.9 | −3.7 | |
| −21.5 | −5.8 | −8 | 10.6 | |
| −0.6 | −0.6 | – | – |
Shareholding pattern
NSE hasn’t returned a shareholding pattern for this company.
Major shareholders
Filings & events
News
No recent news coverage found.